The Viessmann Generations Group (“Viessmann”) has acquired a significant minority stake in European pharmaceutical developer and manufacturer PharOS as part of a shareholder consortium with the investment holding Armira. Headquartered on the outskirts of Athens, Greece, PharOS is a pharmaceutical company that develops, manufactures and supplies generics, over-the-counter and value-added products. The company focuses on hard-to-make generic drugs for key treatment areas such as oncology, central nervous or cardiometabolic diseases. With European production capacities and a resilient supply chain, PharOS is a strategic partner for leading pharmaceutical companies.
Hengeler Mueller team for Viessmann Generation Group
M&A/Corporate: Matthias Hentzen (lead, partner, Düsseldorf), Jan Häller (Frankfurt), Matthias Marz (both senior associates, Düsseldorf),
Public law: Michael Schramm (partner), Jan Schülting (senior associate, both Düsseldorf),
Antitrust: Thorsten Mäger (partner), Anja Balitzki (counsel), Leonie Lentner (associate, all Düsseldorf).
